anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a breast cancer-inhibiting composition containing high amylose starch(HAS) as an active ingredient, and capable of preventing and treating the crisis of the breast cancer. CONSTITUTION: The breast cancer-inhibiting composition as a food composition contains as an active ingredient 10-50wt.%, preferably 20-40wt.%, of the HAS (e.g. hybrid corn) which is a starch containing 40-90wt.% of amylose and 25-40wt.% of slightly digestible components measured by a total dietary fiber- determining method, and further contains other additives such as saccharide, lipid, protein, vitamins, and minerals. The composition can be prepared in the from of foods such as snack confections, block confections, wafers, milk products, miso (salted and fermented soybeans) or in the form of healthy foods such as tablets, syrups, granules or powder. The composition is continuously taken at a dose of 10-70g/day for an adult. The HAS can massively and continuously be taken, because the texture, taste and color of the HAS are better than those of conventional dietary fibers.
The anti-inflammatory and protective cream comprises the structure-forming emulsifier, the fat base, the moistening and softening components, the biologically active additives, the preserving agents, and the water. The water-in-oil emulsifiers are used. Isopropylmyristate or isopropylpalmytate, liquid paraffin and castor oil are used as the fat base. Lanolin is used as the moistening and softening component. The biologically active additives represent the complex of the biologically active substances from the hop cones, the herb of the milfoil, the flowers of the calendula and the chamomile used as carbon dioxide extracts. Germaben II is used as a preserving agent.
This will be multicentre feasibility randomised controlled trial to test the effectiveness of the SF programme in improving family skills outcomes and caregiver and child mental health, as reported by caregivers when implemented in Gilgit-Baltistan. The study will record families' rates of recruitment and attendance to SF programme, evaluate the completeness of programme delivery, cultural acceptability through qualitative interviews and assess the fidelity of training delivery. A small pilot study with N=10 families (a female caregiver (mother) and one child between the age of 8-15 years from each family) will be conducted before main RCT. The study will be conducted in three districts including; Gilgit, Hunza and Skardu in Gilgit Baltistan, Pakistan. We will interview a subset of participants i.e. up to 5 caregivers from each study site (N=15 caregivers) to explore participants' opinions on the acceptability of the programme and to explore any barriers or facilitators to participation.
The invention relates to a pharmaceutical composition for treating brain glioma and belongs to the field of medicines. The pharmaceutical composition which takes artemether and temozolomide as active components comprises the active components in parts by weight: 40-70 parts of artemether and 0.5-4.0 parts of temozolomide, further preferably 65-67 parts of artemether and 0.5-2.0 parts of temozolomide. The pharmaceutical composition provided by the invention has a remarkable inhibiting effect to the C6 cell line of brain glioma of a SD rat cultured in vitro. The effect of using artemether and temozolomide in a combined or independent manner is in time and concentration dependency, and the artemether and temozolomide which are combined in use are in synergic relationship. When the artemether and temozolomide which are combined in use, IC50 value is lower than that when the artemether and temozolomide are independently used. Animal experiments sufficiently prove that when the artemether and temozolomide are combined in use, a good antitumor effect is achieved, and is stronger than that when the artemether and temozolomide are independently used; pathological section results show that when the artemether and temozolomide are combined in use, the quantity of microvessels of brain glioma is remarkably reduced, and the anti-angiogenic effect is stronger than that when the artemether and temozolomide are independently used. The pharmaceutical composition has the advantages of low price, remarkable curative effect and low toxic and side effect.
PURPOSE: A composition for treating or preventing vitiligo which includes longanae arillus extract is provided to induce re-settlement of color in bleaching area by promoting the cell migration to the epithelial tissue. CONSTITUTION: A composition for treating or preventing vitiligo includes longanae arillus extract as active ingredient. The Longanae Arillus extract is extracted as water, C1-C2 of low class alcohol or a mixture thereof. The C1-C2 of low class alcohol is methanol or ethanol. The Longanae Arillus extract induces the differentiation of melanoblast. The Longanae Arillus extract promotes the migration of the melanoblast. The cosmetic composition for preventing or treating the vitiligo includes the Longanae Arillus extract as active ingredient. The external preparation for skin for preventing or improving the vitiligo includes the Longanae Arillus extract as active ingredient.
The invention is concerned with a kind of soft capsule preparation to decrease blood pressure and improve sleeping. It relates to 600 to 700 shares of gastrodia tuber, 600 to 700 shares ofkendir, 600 to 700 shares of seed of spine date, 260 to 360 shares of fox glove, 260 to 360 shares of eucommia bark and 260 to 360 fructus crataegi. This medicine can improve sleeping quality observably, release cases of dizziness, cardio palmus, vexation caused by bad sleeping. It decreases blood pressure slowly instead of suddenly, solves the discomfort feeling in short time and adjusts viscera function radically. After taken this medicine for some time, it will keep the stabilization of blood without to take medicine for all life. It affords double effect to improve sleeping and high blood pressure with pure natural health food, brings good sleeping with high quality and stabilization of blood pressure for long time and improves the sudden raise of blood pressure caused by bad sleeping.
The automatic analysis system for body building training comprises a database, a thermal image acquisition unit and an analysis device. The database is used for storing the training course and the target muscle group data corresponding to the training course. The thermal image acquisition unit is used for acquiring a first thermal image of the user after the exercise course. The analysis device comprises a muscle group identification module, a muscle group temperature calculation module and a comparison module. The muscle group identification module analyzes the first thermal image with a muscle group model to identify a plurality of muscle groups of the user. The muscle group temperature calculation module calculates the muscle group temperatures of the muscle groups respectively to generate main exercise muscle groups when the user exercises the training course. The comparison module is used for comparing the main motor muscle group and the target muscle group data. When the main motor muscle group is not matched with the target muscle group data, the comparison module generates a warning signal.
Chronic hepatitis B virus (HBV) infection continues to be a major public health problem worldwide today. According to statistics, the prevalence of chronic HBV infection assessed globally in 2016 was 3.5%, or 257 million people with chronic infection. In China, it is estimated that about 70 million people are chronically infected with HBV in 2019, including about 20-30 million people with chronic hepatitis B (CHB). CHB is a major risk factor for cirrhosis, and hepatocellular carcinoma (HCC). 12-20% of patients with chronic hepatitis B will develop cirrhosis, and of these, around 20% will further develop decompensated cirrhosis and 6-15% will develop HCC, with hepatitis B accounting for approximately 50% of HCC cases worldwide. Therefore, strongly and exact management of chronic hepatitis B is extremely important for the control of HBV progression. Current domestic and international clinical guidelines generally divide the natural history of chronic hepatitis B into four immune phases based on HBV DNA levels, liver injury, and HBeAg status: immune active, immune tolerant, inactive HBsAg carriers, and reactive stage. The guidelines of American Association for the Study of Liver Diseases (AASLD) recommend the use of antiviral therapy for patients in the immune active and reactive phases, and also provide a detailed follow-up plan for patients in other phases. However, a significant number of patients with chronic hepatitis B cannot be classified in any of these four phases, who falls into a gray area with uncertainty of formal management. According to the 2018 AASLD Hepatitis B Guidelines criteria for antiviral therapy, patients in the gray zone still do not have clarity on the need for antiviral therapy based only on clinical indicators. A recent study showed that nearly 40% of patients with chronic hepatitis B were in the indeterminate stage. At long-term follow-up assessment, half of these patients were still in the indeterminate phase and one-fifth had transitioned to the immune active phase. Patients in the indeterminate phase were 14 times more likely to develop HCC than those with inactive hepatitis B. Therefore, the management of antiviral therapy in patients with CHB in the "gray zone" is crucial and should be demonstrated. The aim of the investigators is to investigate the clinical characteristics of patients with uncertain treatment in the "gray zone" of CHB and to develop a non-invasive predictive model for the indication of antiviral therapy. This will provide guidance for the clinical management of patients in the "gray zone" of CHB, thereby reducing the incidence of cirrhosis and liver cancer and improving their quality of life.
Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
<P>PROBLEM TO BE SOLVED: To provide methods and compositions for the stimulation of immune responses.  <P>SOLUTION: Specifically, the methods and compositions are provided for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines including a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The vaccines against a variety of environmental and human-released pathogens is provided. Here, immunogens are the compositions which are chosen from a group which consists of viruses, bacteria, fungi, and pathogen products originating in viruses, bacteria, or fungi.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention provides a vaccine composition. The vaccine composition comprises the immune dose of Bordetella bronchiseptica pertactin (PRN) protein end N and end C, toxigenic Pasteurellamultocida Pasteurellamultocidatoxin (PMT) toxin protein end N and end C and pharmaceutically acceptable carriers. The vaccine composition has good immunogenicity and can effectively prevent and/or treat atrophic rhinitis of a pig. The invention provides a preparation method of the vaccine composition. Through gene engineering means, a lot of protein antigens are expressed. The vaccine composition has good safety and is conducive to large scale production.
Pharmaceutical compositions such as ointments and creams are provided by admixture of anti- inflammatory steroids active on topical application with a liquid oily phase containing at least one oil possessing a viscosity less than 10 centistokes and in which the steroid has a solubility of at least 0.5% by weight at 25 DEG C, the degree of unsaturation of the steroid in the liquid oily phase of the composition at 25 DEG C being at least 3. Examples of steroids which may be used are betamethasone, beclomethasone and clobetasol derivatives. Suitable oils include esters of mono- and dibasic aliphatic acids. The compositions may include further oils such as liquid paraffin and conventional additives used in the preparation of ointments and creams. The local anti- inflammatory effect of the steroids is maintained in such formulations but systemic side effects are decreased. <IMAGE>
Breast cancer metastasis is responsible for most breast cancer-related deaths and is influenced by many factors within the tumor ecosystem, including tumor cells and microenvironment. Breast cancer stem cells (BCSCs) constitute a small population of cancer cells with unique characteristics, including their capacity for self-renewal and differentiation. Studies have shown that BCSCs not only drive tumorigenesis but also play a crucial role in promoting metastasis in breast cancer. The tumor microenvironment (TME), composed of stromal cells, immune cells, blood vessel cells, fibroblasts, and microbes in proximity to cancer cells, is increasingly recognized for its crosstalk with BCSCs and role in BCSC survival, growth, and dissemination, thereby influencing metastatic ability. Hence, a thorough understanding of BCSCs and the TME is critical for unraveling the mechanisms underlying breast cancer metastasis. In this review, we summarize current knowledge on the roles of BCSCs and the TME in breast cancer metastasis, as well as the underlying regulatory mechanisms. Furthermore, we provide an overview of relevant mouse models used to study breast cancer metastasis, as well as treatment strategies and clinical trials addressing BCSC-TME interactions during metastasis. Overall, this study provides valuable insights for the development of effective therapeutic strategies to reduce breast cancer metastasis.
Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
Ischemia and hypoxia activate astrocytes into reactive types A1 and A2, which play roles in damage and protection, respectively. However, the function and mechanism of A1 and A2 astrocyte exosomes are unknown. After astrocyte exosomes were injected into the lateral ventricle, infarct volume, damage to the blood-brain barrier (BBB), apoptosis and the expression of microglia-related proteins were measured. The dual luciferase reporter assay was used to detect the target genes of miR-628, and overexpressing A2-Exos overexpressed and knocked down miR-628 were constructed. qRT-PCR, western blotting and immunofluorescence staining were subsequently performed. A2-Exos obviously reduced the infarct volume, damage to the BBB and apoptosis and promoted M2 microglial polarization. RT-PCR showed that miR-628 was highly expressed in A2-Exos. Dual luciferase reporter assays revealed that NLRP3, S1PR3 and IRF5 are target genes of miR-628. After miR-628 was overexpressed or knocked down, the protective effects of A2-Exos increased or decreased, respectively. A2-Exos reduced pyroptosis and BBB damage and promoted M2 microglial polarization through the inhibition of NLRP3, S1PR3 and IRF5 via the delivery of miR-628. This study explored the mechanism of action of A2-Exos and provided new therapeutic targets and concepts for treating cerebral ischemia.
Patients treated with ropinirole hydrochloride have reported falling asleep while engaged in activities of daily living, including operation of a motor vehicle which sometimes resulted in accidents (see bolded WARNING).

Other Adverse Events Observed During Phase 2/3 Clinical Trials for RLS: Ropinirole hydrochloride has been administered to 911 individuals in clinical trials. During these trials, all adverse events were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using MedDRA dictionary terminology. These categories are used in the listing below. The frequencies presented represent the proportion of the 911 individuals exposed to ropinirole hydrochloride who experienced events of the type cited on at least one occasion while receiving ropinirole hydrochloride. All reported events that occurred at least twice (or once for serious or potentially serious events), except those already listed, trivial events, and terms too vague to be meaningful, are included without regard to determination of a causal relationship to ropinirole hydrochloride, except that events very unlikely to be drug-related have been deleted.

Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in at least 1/100 patients and infrequent adverse events are those occurring in 1/100 to 1/1,000 patients.
The present invention related to the use of fungi fermentation for inducing mesenchymal-epithelial transitions. It uses fungi as a starter material fermented by Cordyceps species. Its fermentation can induce mesenchymal-epithelial transitions. Chitin is the major component of the fungal cell wall which was fermented by Cordyceps species confirming as N-acetylglucosamine by HPLC analysis. Based on our data shows the fermentation can make the cancer cells along with E-cadherin restore the square epithelial cell form. Proving that the fermentation can actually induce mesenchymal-epithelial transitions.
FIELD: medicine, cosmetics. SUBSTANCE: curative-cosmetic agent comprises the following quantitative ratio of components, wt. -%: topical anesthetic substance, 6.5-20.0; addition stimulating granulation and keratinization of skin surface, 5.0-10.0; ginseng tincture, 6.0-9.0; rosewort root tincture, 3.0-7.0; olive oil, 4.0-12.0; propolis extract, 7.0-15.0; perfume, 0.5-1.0; polyethylene oxide gel, the balance. Dimexide, anesthesine and novocaine are used as topical anesthetic substances and Bergenia pacifica tincture is used as an addition stimulating granulation and keratinization of skin surface. An agent provides effectiveness and prolongation of coition and eliminates the early ejaculation in males due to complex effect of topical anesthetic substances and additions stimulating granulation and keratinization of copulative organ skin surface of man. An agent is applied on skin surface of man copulative organ and used as an external agent. EFFECT: enhanced effectiveness of an agent. 2 cl, 2 ex
PROBLEM TO BE SOLVED: To obtain a retainability imparting agent, enabling the adherence and retention of a drug on a protein surface for a long time by compounding an extract of a plant belonging to the genus Murraya. SOLUTION: An extract of a plant of Rutaceae Murraya, e.g. an extract obtained by extracting one or more kinds selected from leaves, fruits, branches, trunks, barks, roots, root barks, etc., of Murraya koenigii Spreng, etc., with a solvent (e.g. methanol) according to a conventional process and preferably removing the solvent from the resultant extraction mixture by distillation, is used as a retainability imparting agent. Compounding of the retainability imparting agent in an external preparation in an amount of 0.0001-5wt.% imparts a medicinal agent such as triclosan, a chlorhexidine or cetylpyridinium chloride with retainability by allowing them to adhere and retain on the surface of protein of the skin, the mucosa, nails, hair, etc.  The agent compounded in the external preparation is not easily washed out by a secreted matter such as sweat, saliva, etc., water, etc., and accordingly it can exhibit the pharmaceutical activity for a long time. Further, a plant of the genus Murraya has been used as a spice, and it is excellent in safety.
This study aimed to evaluate age as a prognostic factor and develop a comprehensive prognostic model for patients undergoing clipping surgery for World Federation of Neurosurgical Societies (WFNS) grade I/II aneurysmal subarachnoid haemorrhage (SAH). We retrospectively investigated 188 patients with WFNS grade I/II SAH who underwent microsurgical clipping at our institute between December 2010 and January 2020. The data of 176 patients (75 with grade I and 101 with grade II) were analysed. Data on patient demographics, aneurysm characteristics, SAH factors, surgical details, and clinical outcomes were collected. Prognostic factors were assessed using bivariate and multivariable logistic regression analyses, and recursive partitioning analysis. Favourable outcomes (mRS 0-2) were observed in 76% of patients. Age, a significant negative prognostic factor in multivariable analysis (odds ratio 0.55, 95% confidence interval 0.40-0.76, p < 0.001), was cutoff at 70 years by the receiver operating characteristic curve. Patients aged ≤ 70 years had significantly better outcomes than those aged > 70 years (84% vs. 46%, respectively; p < 0.001). Epileptic seizures were significantly associated with poor outcomes in older adults (p < 0.001). A prognostic model (favourable, intermediate, and poor) based on age and postoperative adverse events showed significantly different outcomes between age groups (p < 0.001). Age was a stronger prognostic factor than WFNS grading for patients with grade I/II SAH undergoing microsurgical clipping. For patients aged ≤ 70 years, precise microsurgeries with fewer complications were associated with favourable outcomes beyond WFNS grade. For older patients, postoperative intensive seizure management may prevent poor outcomes.
<P>PROBLEM TO BE SOLVED: To provide an attenuated form of bovine viral diarrhea (BVD) virus and a method for producing the same.  <P>SOLUTION: The method for producing the attenuated form of the BVD virus comprises mutating an N<SP>pro</SP>protease gene. The attenuated form of virus is prepared by the method. An antibody is prepared by the virus. A vaccine usable for immunizing a ruminant is provided.  <P>COPYRIGHT: (C)2003,JPO